Home › Funds › Soleus Capital Management, L.P. › NVCR

Soleus Capital Management, L.P. position in NVCR

NOVOCURE LTD · Health Care

Soleus Capital Management, L.P. reported holding 9,913,401 shares of NVCR (NOVOCURE LTD) in its Q2 2026 13F filing — a position valued at US$150.2M, representing 5.18% of its reported portfolio and ranking #5 among its reported holdings. Soleus Capital Management, L.P. has disclosed NVCR holdings in 11 of the last 12 reported quarters, going back to Q3 2023.

Latest position (Q2 2026)9.91M sh
Reported value held$150.19M
Portfolio Weight5.18%
First reportedQ3 2023
Last changeReduce
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Soleus Capital Management, L.P.'s NVCR position evolved

Soleus Capital Management, L.P. first disclosed a stake in NVCR in Q3 2023 at 344,100 shares (US$5.6M). The position peaked in Q2 2026 at 9,913,401 shares, worth US$150.2M. Across 11 filings, Soleus Capital Management, L.P. increased the stake 5 time(s), trimmed it 4 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 9,913,401 shares valued at US$150.2M — a reduction of -578,990 shares quarter over quarter.. Notable position changes include a 131% increase in Q1 2024 (shares rose 10% over the following quarter), a 84% trim in Q2 2024 (shares fell 9% over the following quarter), a 102% increase in Q1 2025 (shares were roughly flat over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 344.10K $5.56M New
Q4 2023 301.00K $4.49M Reduce
Q1 2024 695.76K $10.87M Add
Q2 2024 108.90K $1.87M Reduce
Q4 2024 2.74M $81.64M New
Q1 2025 5.52M $98.39M Add
Q2 2025 6.90M $122.90M Add
Q3 2025 9.64M $124.61M Add
Q4 2025 8.53M $110.30M Reduce
Q1 2026 10.49M $114.37M Add
Q2 2026 9.91M $150.19M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About NVCR and 13F data

NVCR (NOVOCURE LTD) is a Health Care company. 31 other funds we track also report a position in NVCR — the largest reported positions include Palo Alto Investors LP (US$19.4M), C WorldWide Group Holding A/S (US$14.7M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding NVCR

All NVCR fund holders →

FAQ

How long has Soleus Capital Management, L.P. held NVCR?

Soleus Capital Management, L.P. has disclosed NVCR holdings in 11 of the last 12 reported quarters, going back to Q3 2023.

What is Soleus Capital Management, L.P.'s current position in NVCR?

As of Q2 2026, Soleus Capital Management, L.P. holds 9.91M shares of NVCR (NOVOCURE LTD), valued at $150.19M, representing 5.18% of its reported portfolio and ranking #5.

Has Soleus Capital Management, L.P. been buying or selling NVCR?

In the latest 13F filing (Q2 2026), Soleus Capital Management, L.P. reduced its position in NVCR. The position peaked in Q2 2026 at 9.91M shares.

Which other funds hold NVCR?

Other major institutional holders of NVCR include Palo Alto Investors LP, C WorldWide Group Holding A/S, among 31 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.